![(1R,2S,9S)-7,11-Diazatricyclo[7.3.1.0,2,7]tridecan-6-one](https://static.cymitquimica.com/products/3D/img/TAA16194.png "Click to enlarge")
(1R,2S,9S)-7,11-Diazatricyclo[7.3.1.0,2,7]tridecan-6-one
CAS: 18161-94-9
Ref. 3D-TAA16194
| 1g | Discontinued | ||
| 5g | Discontinued | ||
| 50mg | Discontinued | ||
| 100mg | Discontinued | ||
| 250mg | Discontinued | ||
| 500mg | Discontinued |
Product Information
Name:
(1R,2S,9S)-7,11-Diazatricyclo[7.3.1.0,2,7]tridecan-6-one
Synonyms:
- 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, decahydro-, [1R-(1α,5α,11aα)]-
- Tetrahydrocytisine
- Cytisine, tetrahydro-
- (1R,5S,11aS)-Decahydro-1,5-methano-8H-pyrido[1,2-a][1,5]diazocin-8-one
- 1,5-Methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, decahydro-, (1R,5S,11aS)-
Description:
(1R,2S,9S)-7,11-Diazatricyclo[7.3.1.0,2,7]tridecan-6-one is a receptor subtype that binds to the n-methylcytisine binding site on the acetylcholine receptor. It is synthesized using solid phase synthesis and has been used as an affinity ligand for combinatory studies with other drugs that target nicotinic acetylcholine receptors (nAChRs). The compound has been shown to be selective for the α4β2 subtype of nAChRs in the Xenopus oocyte system and also inhibits quinolizidine alkaloid biosynthesis in vitro at high concentrations. The reaction time required for this synthesis is shorter than that of other synthetic schemes.
Notice:
Our products are intended for lab use only. For any other use, please contact us.
Brand:
Biosynth
Long term storage:
Notes:
Chemical properties
Molecular weight:
194.27 g/mol
Formula:
C11H18N2O
Purity:
Min. 95%
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:
